|Articles|February 1, 2002

New Approaches to the Treatment of Migraine: Clinical and Economic Impact
Volume 8
Issue 3 Suppl

Migraine: Diagnosis, Management, and New Treatment Options

Author(s)R. Michael Gallagher, DO, F. Michael Cutrer, MD

Download PDF: Migraine: Diagnosis, Management, and New Treatment Options

Articles in this issue

almost 24 years ago

Article

Participating Faculty

almost 24 years ago

Article

Introduction

almost 24 years ago

Article

Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability

almost 24 years ago

Article

Economic Comparison of Oral Triptans for Management of Acute Migraine: Implications for Managed Care

almost 24 years ago

Article

Health Outcomes Evaluations: Estimating the Impact of Almotriptan in Managed Care Settings

almost 24 years ago

Article

Almotriptan Versus Sumatriptan in Migraine Treatment: Direct Medical Costs of Managing Adverse Chest Symptoms

almost 24 years ago

Article

Cost Savings in Migraine Associated with Less Chest Pain on New Triptan Therapy

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

HEDIS Glycemic Goal Achieved Using Control-IQ Technology

ByBimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Miranda R. Polin, MS, BS,Irl B. Hirsch, MD,Laya Ekhlaspour, MD,Steve Edelman, MD,Diana I. Brixner, PhD, RPh,Charles Stemple, DO

December 22nd 2025

Linking Data to Determine Risk for 30-Day Readmissions in Dementia

ByPamela S. Roberts, PhD, OTR/L,Chih-Ying Li, PhD, OTR/L,Debra S. Ouellette, MS, OTR/L,Nabeel Qureshi, MPH,Erica Spivack, MHA,Mary Nasmyth, MD,Nancy L. Sicotte, MD,Zaldy S. Tan, MD

December 22nd 2025

Performance of 2-Stage Health-Related Social Needs Screening Using Area-Level Measures

ByJoshua R. Vest, PhD, MPH,Christopher A. Harle, PhD,Justin Blackburn, PhD

December 19th 2025

Impact of Medicaid Institution for Mental Diseases Exclusion on Serious Mental Illness Outcomes

ByOnur Baser, PhD, MS,Heidi C. Waters, PhD,Nehir Yapar, BS,Katarzyna Rodchenko, MA, MPH,Lauren Isenman, MPH,Xue Han, PhD,Deborah Freedman, MBA,Rashmi Patel, MD, PhD

December 17th 2025

Physician-Pharmacy Integration in Cancer Care: Pillars of Medically Integrated Pharmacy

ByGury K. Doshi, MD,Lucio Gordan, MD,Kirollos Hanna, PharmD,Scott Freeswick, PharmD,Natalie Dickson, MD,Desi Kotis, PharmD,Osama Abdelghany, PharmD, MHA,Ken Komorny, PharmD,Neal Dave, PharmD,Michael Reff, RPh, MBA

Migraine: Diagnosis, Management, and New Treatment Options

Articles in this issue

Newsletter

Related Content

HEDIS Glycemic Goal Achieved Using Control-IQ Technology

Linking Data to Determine Risk for 30-Day Readmissions in Dementia

Performance of 2-Stage Health-Related Social Needs Screening Using Area-Level Measures

Impact of Medicaid Institution for Mental Diseases Exclusion on Serious Mental Illness Outcomes

Physician-Pharmacy Integration in Cancer Care: Pillars of Medically Integrated Pharmacy

Trending on AJMC

Visibility, Not Lesion Burden, Drives Distress in Alopecia Areata

Top 5 Most-Read CLL Articles of 2025

Top 5 Most-Read Dermatology Content of 2025

Top 5 Most-Read "5 Things" Articles of 2025

ICYMI: Highlights From ASH 2025